Jamjoom Pharma Nine-Month Profit Rises 5.1%
Jeddah, Saudi Arabia — Jamjoom Pharmaceuticals Factory Co. posted net profit of 416.05 million SAR for the nine months ending September 30, 2026, up 5.1% from 395.73 million SAR in the same period a year earlier. Revenue climbed 7.1% to 1,281.36 million SAR, driven by volume growth in Saudi Arabia, Iraq, and Gulf markets. Gross […] The post Jamjoom Pharma Nine-Month Profit Rises 5.1% appeared…
Jamjoom Pharmaceuticals Factory Co. reported a 5.1% increase in net profit to 416.05 million SAR over nine months ending September 30, 2026, compared to 395.73 million SAR in the same period last year. Revenue grew 7.1% to 1,281.36 million SAR, boosted by volume growth in Saudi Arabia, Iraq, and Gulf markets. Gross profit rose 9.9% to 826.91 million SAR, indicating improved production efficiency.
Third-quarter revenue was 354.66 million SAR, up 3.6% year-over-year, while net profit increased 3.3% to 110.21 million SAR. However, both figures decreased sharply from the previous quarter, with revenue down 20.4% and net profit falling 19.9% due to summer seasonality, pharmacy restocking, declining private-market demand, and geopolitical factors.
Total comprehensive income for shareholders dropped 30.6% quarter-on-quarter to 103.21 million SAR. The nine-month gross margin expanded to 64.5%, driven by a favorable product mix and geographic distribution. Dermatology, Cardiometabolic, and Ophthalmology therapeutic areas contributed to portfolio growth, with Saudi Arabia and Iraq driving revenue increases.
However, rising operating expenses, seen as growth investments, need to translate into revenue gains in future quarters for investors to remain confident. Investors should monitor whether Q4 performance rebounds or signals a long-term demand slowdown in key markets.
Written by urgent.news from The Saudi Standard's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
